Do I need a prescription for Tipranavir 250mg capsules?

Tipranavir 250mg capsules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Tipranavir 250mg capsules?

Tipranavir 250mg capsules is the generic name. It is available under brand names including: Aptivus 250mg capsules. (Source: NHS dm+d — Actual Medicinal Products)

Tipranavir 250mg capsules

Capsule

250mg

Oral

Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease.

Active ingredients:

Tipranavir

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 05.03.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC J05AE09

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Tipranavir

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Tipranavir

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Tipranavir

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Tipranavir on the MHRA register

Aptivus 250mg capsules

Boehringer Ingelheim Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Daily doseShow details

WHO defined daily dose (DDD)

1 gram

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets

Tablet

150mg

Same therapeutic group

Ritonavir 100mg oral powder sachets sugar free

Powder

100mg

Same therapeutic group

Darunavir 800mg tablets

Tablet

800mg

Same therapeutic group

Darunavir 100mg/ml oral suspension sugar free

Oral suspension

100mg

Same therapeutic group

Ritonavir 100mg tablets

Tablet

100mg

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Tipranavir

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Tipranavir

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

41771811000001105

dm+d ID

41771811000001105

VTM (Virtual Therapeutic Moiety)

777783006

VMP (Virtual Medicinal Product)

41771811000001105

BNF code

05030100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

J05AE09

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

70 found

Half-life

5-6 hours

Mechanism

Tipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the pr…

Food interactions

1 warning

Human targets

None mapped

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Absorption is limited, although no absolute quantification of absorption is available.

Half-life

5-6 hours

5-6 hours

Protein binding

99.9%

Extensive (> 99.9%), to both human serum albumin and α-1-acid glycoprotein.

Metabolism

Hepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.

Properties:

solid

Avg. mass: 602.66 Da

View FDA drug label

DrugBank indication

For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

Also known as(88)

Tipranavir

Pr160Gag-Pol

(R)-limonene 6-monooxygenase

(S)-limonene 6-monooxygenase

(S)-limonene 7-monooxygenase

1.14.14.1

CYPIIC17

CYPIIC19

Dosage forms(6)

(Oral) — 250 mg

Capsule (Oral) — 250 mg

Capsule (Oral) — 250.000 mg

Capsule, liquid filled (Oral) — 250 mg/1

Solution (Oral) — 100 mg/1mL

Solution (Oral) — 100 MG/ML

Molecular properties(19)

Drug interactions(1345)

Known interactions with other medications. Always consult a healthcare professional.

Lepirudin

Major

DB00001

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.

Check this interaction

Bivalirudin

Major

DB00006

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Bivalirudin.

Check this interaction

Alteplase

Major

DB00009

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Alteplase.

Check this interaction

Urokinase

Major

DB00013

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Urokinase.

Check this interaction

Reteplase

Major

DB00015

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reteplase.

Check this interaction

Anistreplase

Major

DB00029

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Anistreplase.

Check this interaction

Tenecteplase

Major

DB00031

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tenecteplase.

Check this interaction

Drotrecogin alfa

Major

DB00055

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Drotrecogin alfa.

Check this interaction

Streptokinase

Major

DB00086

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Streptokinase.

Check this interaction

Dicoumarol

Major

DB00266

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dicoumarol.

Check this interaction

Argatroban

Major

DB00278

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Argatroban.

Check this interaction

Ardeparin

Major

DB00407

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ardeparin.

Check this interaction

Phenindione

Major

DB00498

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Phenindione.

Check this interaction

Fondaparinux

Major

DB00569

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Fondaparinux.

Check this interaction

Warfarin

Major

DB00682

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Warfarin.

Check this interaction

Pentosan polysulfate

Major

DB00686

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Pentosan polysulfate.

Check this interaction

Phenprocoumon

Major

DB00946

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Phenprocoumon.

Check this interaction

Heparin

Major

DB01109

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Heparin.

Check this interaction

Enoxaparin

Major

DB01225

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Enoxaparin.

Check this interaction

Acenocoumarol

Major

DB01418

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Acenocoumarol.

Check this interaction

4-hydroxycoumarin

Major

DB03410

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with 4-hydroxycoumarin.

Check this interaction

Coumarin

Major

DB04665

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Coumarin.

Check this interaction

Ximelagatran

Major

DB04898

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ximelagatran.

Check this interaction

Desmoteplase

Major

DB04925

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Desmoteplase.

Check this interaction

Ancrod

Major

DB05099

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ancrod.

Check this interaction

Rivaroxaban

Major

DB06228

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Rivaroxaban.

Check this interaction

Sulodexide

Major

DB06271

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Sulodexide.

Check this interaction

Semuloparin

Major

DB06294

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Semuloparin.

Check this interaction

Idraparinux

Major

DB06406

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Idraparinux.

Check this interaction

Astaxanthin

Major

DB06543

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Astaxanthin.

Check this interaction

Apixaban

Major

DB06605

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Apixaban.

Check this interaction

Otamixaban

Major

DB06635

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Otamixaban.

Check this interaction

Amediplase

Major

DB06679

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Amediplase.

Check this interaction

Danaparoid

Major

DB06754

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Danaparoid.

Check this interaction

Dalteparin

Major

DB06779

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dalteparin.

Check this interaction

Tinzaparin

Major

DB06822

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Tinzaparin.

Check this interaction

(R)-warfarin

Major

DB08496

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with (R)-warfarin.

Check this interaction

Ethyl biscoumacetate

Major

DB08794

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ethyl biscoumacetate.

Check this interaction

Nadroparin

Major

DB08813

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Nadroparin.

Check this interaction

Ditazole

Major

DB08994

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Ditazole.

Check this interaction

Sodium citrate

Major

DB09154

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Sodium citrate.

Check this interaction

Dextran

Major

DB09255

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Dextran.

Check this interaction

Bemiparin

Major

DB09258

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Bemiparin.

Check this interaction

Parnaparin

Major

DB09260

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Parnaparin.

Check this interaction

Desirudin

Major

DB11095

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Desirudin.

Check this interaction

Antithrombin Alfa

Major

DB11166

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin Alfa.

Check this interaction

Protein C

Major

DB11312

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Protein C.

Check this interaction

Antithrombin III human

Major

DB11598

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Antithrombin III human.

Check this interaction

Letaxaban

Major

DB11984

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Letaxaban.

Check this interaction

Darexaban

Major

DB12289

The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Darexaban.

Check this interaction

Showing 50 of 1345 interactions

Food & lifestyle interactions

Advice

Take with or without food. However, if taken with ritonavir tablets, tipranavir should be taken with food.

Toxicity & overdose

Oral LD₅₀ in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

How it works

Mechanism of action

Tipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. Two mechanisms are suggested in regards to the potency of tipranavir: 1. Tipravanir may bind to the active site of the protease enzyme with fewer hydrogen bonds than peptidic protease inhibitors, which results in increased flexibility, allowing it to fit into the active site of the enzyme in viruses that have become resistance to other protease inhibitors. This also enables tipranavir to adjust to amino acid substitutions at the active site. 2. Tipranavir's strong hydrogen bonding interaction with the amide backbone of the protease active site Asp30 may lead to its activity against resistant viruses.

Pharmacodynamics

Tipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Absorption is limited, although no absolute quantification of absorption is available.

Half-life

5-6 hours

Protein binding

Extensive (> 99.9%), to both human serum albumin and α-1-acid glycoprotein.

Metabolism

Hepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.

Metabolizing enzymes(4)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2C19Cytochrome P450 2C19

substrate

inhibitor

UGT1A1UDP-glucuronosyltransferase 1A1

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

CYP2D6Cytochrome P450 2D6

substrate

inhibitor

Transporters(5)

Proteins that transport this drug across cell membranes

Bile salt export pump

BE0000703

ABCB11

substrate

inhibitor

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

Solute carrier organic anion transporter family member 2B1

BE0001042

SLCO2B1

inhibitor

Specific functionbile acid transmembrane transporter activity

Cellular location

Cell membrane

General function & pharmacology

Mediates the Na(+)-independent transport of steroid sulfate conjugates and other specific organic anions .
PMID:10873595 PMID:11159893 PMID:11932330 PMID:12724351 PMID:14610227 PMID:16908597 PMID:18501590 PMID:20507927 PMID:22201122 PMID:23531488 PMID:25132355 PMID:26383540 PMID:27576593 PMID:28408210 PMID:29871943 PMID:34628357

Responsible for the transport of estrone 3-sulfate (E1S) through the basal membrane of syncytiotrophoblast, highlighting a potential role in the placental absorption of fetal-derived sulfated steroids including the steroid hormone precursor dehydroepiandrosterone sulfate (DHEA-S) .
PMID:11932330 PMID:12409283
Also facilitates the uptake of sulfated steroids at the basal/sinusoidal membrane of hepatocytes, therefore accounting for the major part of organic anions clearance of liver .
PMID:11159893
Mediates the intestinal uptake of sulfated steroids .
PMID:12724351 PMID:28408210
Mediates the uptake of the neurosteroids DHEA-S and pregnenolone sulfate (PregS) into the endothelial cells of the blood-brain barrier as the first step to enter the brain .
PMID:16908597 PMID:25132355
Also plays a role in the reuptake of neuropeptides such as substance P/TAC1 and vasoactive intestinal peptide/VIP released from retinal neurons .
PMID:25132355
May act as a heme transporter that promotes cellular iron availability via heme oxygenase/HMOX2 and independently of TFRC .
PMID:35714613
Also transports heme by-product coproporphyrin III (CPIII), and may be involved in their hepatic disposition .
PMID:26383540
Mediates the uptake of other substrates such as prostaglandins D2 (PGD2), E1 (PGE1) and E2 (PGE2), taurocholate, L-thyroxine, leukotriene C4 and thromboxane B2 (PubMed:10873595, PubMed:14610227, PubMed:19129463, PubMed:29871943, Ref.25). May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable). Shows a pH-sensitive substrate specificity which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment .
PMID:14610227 PMID:19129463 PMID:22201122

The exact transport mechanism has not been yet deciphered but most likely involves an anion exchange, coupling the cellular uptake of organic substrate with the efflux of an anionic compound .
PMID:19129463 PMID:20507927 PMID:26277985

Hydrogencarbonate/HCO3(-) acts as a probable counteranion that exchanges for organic anions .
PMID:19129463
Cytoplasmic glutamate may also act as counteranion in the placenta .
PMID:26277985
An inwardly directed proton gradient has also been proposed as the driving force of E1S uptake with a (H(+):E1S) stoichiometry of (1:1) PMID:20507927

Solute carrier organic anion transporter family member 1B1

BE0001004

SLCO1B1

inhibitor

Specific functionbile acid transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Mediates the Na(+)-independent uptake of organic anions .
PMID:10358072 PMID:15159445 PMID:17412826

Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-thyronine) .
PMID:10358072 PMID:10601278 PMID:10873595 PMID:11159893 PMID:12196548 PMID:12568656 PMID:15159445 PMID:15970799 PMID:16627748 PMID:17412826 PMID:19129463 PMID:26979622

Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop .
PMID:22232210
Involved in the clearance of endogenous and exogenous substrates from the liver .
PMID:10358072 PMID:10601278
Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition .
PMID:26383540
May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins), such as pravastatin and pitavastatin, a clinically important class of hypolipidemic drugs .
PMID:10601278 PMID:15159445 PMID:15970799

May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drug methotrexate .
PMID:23243220
May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver .
PMID:16624871 PMID:16627748
Shows a pH-sensitive substrate specificity towards prostaglandin E2 and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment .
PMID:19129463
Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions PMID:19129463

Solute carrier organic anion transporter family member 1B3

BE0003659

SLCO1B3

inhibitor

Specific functionbile acid transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Mediates the Na(+)-independent uptake of organic anions .
PMID:10779507 PMID:15159445 PMID:17412826

Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (17-beta-glucuronosyl estradiol, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate), as well as eicosanoid leukotriene C4, prostaglandin E2 and L-thyroxine (T4) .
PMID:10779507 PMID:11159893 PMID:12568656 PMID:15159445 PMID:17412826 PMID:19129463

Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions .
PMID:19129463
Shows a pH-sensitive substrate specificity towards sulfated steroids, taurocholate and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment .
PMID:19129463
Involved in the clearance of bile acids and organic anions from the liver .
PMID:22232210
Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop .
PMID:22232210
Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition .
PMID:26383540
May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins) such as pitavastatin, a clinically important class of hypolipidemic drugs .
PMID:15159445
May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drugs methotrexate and paclitaxel .
PMID:23243220
May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver PMID:16624871 PMID:16627748

ATP-dependent translocase ABCB1

BE0001032

ABCB1

substrate

inhibitor

inducer

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Scientific references(4)

Doyon L., Tremblay S., Bourgon L., Wardrop E., Cordingley M.G.

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

Antiviral Research

200568(1):27-35. doi: 10.1016/j.antiviral.2005.07.003

PMID: 16122817 DOI: 10.1016/j.antiviral.2005.07.003

Authors unspecified

Tipranavir.

Drugs in R & D

20067(1):55-62. doi: 10.2165/00126839-200607010-00005

PMID: 16620137 DOI: 10.2165/00126839-200607010-00005

Temesgen Z., Feinberg J.

Tipranavir: A New Option for the Treatment of Drug-Resistant HIV Infection.

Clinical Infectious Diseases

200745(6):761-769. doi: 10.1086/520847

PMID: 17712762 DOI: 10.1086/520847

Luna B., Townsend M.U.

Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

Clinical Therapeutics

200729(11):2309-2318. doi: 10.1016/j.clinthera.2007.11.007

PMID: 18158073 DOI: 10.1016/j.clinthera.2007.11.007

ATC classification(1 code)

ATC J05AE09

Affected organisms(1)

Human Immunodeficiency Virus

Salt forms(1)

Tipranavir disodium(DBSALT001882)

Experimental properties(2)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(9)

Commercial products(4)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Tipranavir

DB00932

CAS number

174484-41-4

UNII (FDA)

ZZT404XD09

InChI Key (molecular fingerprint)

SUJUHGSWHZTSEU-FYBSXPHGSA-N

Additional database identifiers

Drugs Product Database (DPD)

12684

ChEBI

63628

PubChem Compound

54682461

PubChem Substance

46506257

ChemSpider

10482313

BindingDB

50479982

PharmGKB

PA163522473

PDB

TPV

Therapeutic Targets Database

DAP001085

Wikipedia

Tipranavir

ChEMBL

CHEMBL222559

ZINC

ZINC000100016058

RxCUI

190548

UniProtKB

Q72874

UniProt Accession

Q72874_HV1

GenBank Gene Database

M15654

GenBank Protein Database

326388

UniProtKB

P03366

UniProt Accession

POL_HV1B1

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12530

GeneCards

UGT1A1

GenBank Gene Database

M57899

GenBank Protein Database

184473

Guide to Pharmacology

2990

UniProtKB

P22309

UniProt Accession

UD11_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10962

GenAtlas

SLCO2B1

GeneCards

SLCO2B1

GenBank Gene Database

AB026256

GenBank Protein Database

5006263

Guide to Pharmacology

1224

UniProtKB

O94956

UniProt Accession

SO2B1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10959

GenAtlas

SLCO1B1

GeneCards

SLCO1B1

GenBank Gene Database

AF060500

GenBank Protein Database

5051630

Guide to Pharmacology

1220

UniProtKB

Q9Y6L6

UniProt Accession

SO1B1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10961

GeneCards

SLCO1B3

GenBank Gene Database

AJ251506

GenBank Protein Database

9187497

Guide to Pharmacology

1221

UniProtKB

Q9NPD5

UniProt Accession

SO1B3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $4.29/ml

To $1271.80/bottle

Aptivus 100 mg/ml solution

$4.29/ml

Aptivus 250 mg capsule

$10.19/capsule

Aptivus 120 250 mg capsule Bottle

$1271.80/bottle

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

All patents expired, 6 expired

6147095

United States

Paediatric ext.

Approved 14 Nov 2000 · Expires 29 Apr 2020

Expired

5852195

United States

Paediatric ext.

Approved 22 Dec 1998 · Expires 22 Dec 2019

Expired

6231887

United States

Paediatric ext.

Approved 15 May 2001 · Expires 27 Jan 2019

Expired

2294033

Canada

Approved 9 Jan 2007 · Expires 27 Jul 2018

Expired

2187523

Canada

Approved 21 Nov 2006 · Expires 4 May 2015

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Tipranavir 250mg capsules

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Clinical essentials

Pharmacology

Deep science
9

Chemical identifiers

Tipranavir

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Tipranavir 250mg capsules

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Clinical essentials

Pharmacology

Deep science9

Chemical identifiers

Tipranavir

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
9